Copyright
©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Jan 14, 2014; 20(2): 436-444
Published online Jan 14, 2014. doi: 10.3748/wjg.v20.i2.436
Published online Jan 14, 2014. doi: 10.3748/wjg.v20.i2.436
Is hepatitis B-virucidal validation of biocides possible with the use of surrogates?
Andreas Sauerbrei, Institute of Virology and Antiviral Chemotherapy, Jena University Clinic, Friedrich Schiller University of Jena, D-07745 Jena, Germany
Author contributions: Sauerbrei A acquired, analyzed and interpreted data, drafted and revised the article.
Correspondence to: Dr. Andreas Sauerbrei, Professor, Institute of Virology and Antiviral Chemotherapy, Jena University Clinic, Friedrich Schiller University of Jena, Hans-Knoell-Straße 2, D-07745 Jena, Germany. andreas.sauerbrei@med.uni-jena.de
Telephone: +49-3641-9395700 Fax: +49-3641-9395702
Received: July 23, 2013
Revised: September 30, 2013
Accepted: November 28, 2013
Published online: January 14, 2014
Revised: September 30, 2013
Accepted: November 28, 2013
Published online: January 14, 2014
Core Tip
Core tip: There is a need for disinfectants with proven virucidal activity against the hepatitis B virus (HBV). Feasible HBV infectivity assays are not available; therefore, the establishment of surrogate models for HBV infection is of high importance. This paper reviews the application of the most promising and feasible assay, the use of the duck hepatitis B virus, which can be propagated in vitro in primary duck embryonic hepatocytes. The paper also describes how and why this model can be used to evaluate the efficacy of disinfectants against HBV.